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2214-031X/Copyright ª 2015, The Aut
license (http://creativecommons.org/Summary Transdermal glyceryl trinitrate patches have been investigated as an alternative
therapeutic intervention for a range of tendinopathies, due to the ease of titration of dosage
and the ease of their application. Glyceryl trinitrate has been inferred to reduce pain and
inflammation secondary to their nitric oxide-producing action. Shoulder impingement syn-
drome is a soft tissue condition that manifests as anterior shoulder pain, weakness, and diffi-
culty in daily activities. This review will evaluate the efficacy of glyceryl trinitrate patches in
treating a variety of rotator cuff tendinopathies related to shoulder impingement, based on
human and animal trials, and suggest its practical application in future trials and management.
Copyrightª 2015, The Authors. Published by Elsevier (Singapore) Pte Ltd. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Shoulder impingement syndrome (SIS) encompasses a range
of pathologies and can simply be defined as a soft tissue
condition characterised by entrapment of the rotator cuff
soft tissues, including tendons and subacromial bursa, be-
tween the coracoacromial arch and the humeral head [1].
It manifests as anterior shoulder pain, weakness, andf New South Wales, Sydney,
om (Y. Assem).
.11.001
hors. Published by Elsevier (Singa
licenses/by-nc-nd/4.0/).difficulty in daily activities as a consequence of decreased
range of motion (ROM) [2].
This syndrome is managed by either conservative
methods (consisting of activity modification and short pe-
riods of rest, rotator cuff muscle strengthening, and anti-
inflammatory medications) or surgical intervention, both of
which are well detailed in the literature [3]. Clinical
outcome measures include comparative Visual Analogue
Scale (VAS) pain scores, American Shoulder and Elbow
Surgery scores, Disability of the Arm Shoulder and Hand
scores, ROM, power, and standardised shoulder function
tests at different time points, pre- and postintervention.
Glyceryl trinitrate (GTN) patches have been a thera-
peutic intervention in angina pectoris for over a century.pore) Pte Ltd. This is an open access article under the CC BY-NC-ND
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range of tendinopathies due to the ease of titration of
dosage and the ease of their application [4,5]. These
patches have been inferred to reduce pain and inflamma-
tion secondary to their nitric oxide (NO)-producing action
[6]. This review will evaluate the efficacy of GTN patches in
treating a variety of shoulder pathologies, based on human
and animal trials, and suggest its practical applications in
future trials and management.
NO is an enzymatically produced free radical, which
functions as a messenger molecule in small physiological
quantities [7]. NO production is dependent on the family of
enzymes nitric oxide synthase (NOS), comprising three
cofactor-regulated isoforms: eNOS, bNOS, and iNOS, an
inducible isoform critical in host defence [7].
Tendon healing relies upon the production of collagen
via fibroblasts, and it is thought that NO plays an important
role in stimulating collagenous repair [4].
There is limited endogenous generation of NOS in
normal tendons; however, it has been demonstrated to
be induced in tendon injury [8]. Inhibition of NO has been
observed to decrease collagen content and synthesis via
fibroblasts, through the systemic inhibition of NOS,
resulting in a reduced cross-sectional area of tendon
healing histologically [9,10]. In accordance, addition of
exogenous NO has been shown to augment tendon heal-
ing, improving extracellular collagen matrix organisation
[4,11].Figure 1 Flow chart demonstrating the mechanism of action of G
CRAAP Z currency, relevance, authority, accuracy, and purpose; PNO’s involvement in optimising collagen deposition is
reinforced through experimentation with human tendon
cell cultures, where small doses of exogenous NO and iNOS
were shown to enhance collagen and total protein synthesis
in vitro [12]. The aforementioned mechanisms are
demonstrated in greater detail in the NO animal studies
discussed later.Glyceryl trintrate pharmacokinetics
GTN patches are a potential, easy-to-apply, noninvasive
alternative to standard nonoperative treatment options for
SISs. GTN is a prodrug; its pharmacological action is
attributed to its biotransformation into NO via metabolic
enzymes and the consequent localised exogenous NO
secretion [5]. The mechanism of NO augmentation in
collagen deposition has been discussed previously, and it is
postulated that reduction in pain post injury corresponds to
enhanced collagen synthesis, an effect potentially extrap-
olated to GTN patches on impingement syndromes (Fig. 1)
[9].
The transdermal patch is applied on the skin proximal to
the site of pain or tenderness, delivering GTN at a constant
rate [7]. The GTN plasma concentration is maintained over
a period of 24 hours, via continuous absorption into
vasculature, albeit interindividual variation exists [5]. It is
considered a “safe” treatment, due to the absence ofTN patches in tendon healing explored throughout this review.
ICO Z population, intervention, control, and outcome.
14 Y. Assem, M. Arorasevere or chronic adverse events, with symptoms primarily
constituting of headaches and mild rash, characterised by
their “reversal upon cessation” nature [9]. The adminis-
trating dosage can be titrated simply to facilitate the
treatment intention, in the context of the clinical trials
below a 5 mg/24-hour patch is subdivided into equal quar-
terly 1.25 mg/24-hour patches, replaced daily [14].Treatment rationale
The presentation of shoulder impingement is often con-
current to rotator cuff tendinitis, and may progress to
chronic inflammation or tendinopathy if it remains un-
treated [17]. Thus, a mainstay of treatment involves
restoring rotator cuff function [18]. A systematic approach
to rehabilitation of SIS is divisible into three chronological
stages: the initial reduction of pain and inflammation, fol-
lowed by the maintenance of the “normal” ROM, and finally
strengthening of the involved and supporting rotator cuff
muscles [17].
Thus, the therapeutic effect of transdermal GTN on
shoulder impingement may be attributed to the role it plays
in augmenting tendon remodelling and healing, which will
cause a natural decline in inflammation of the affected
rotator cuff tendon, reducing the symptoms associated
with impingement and discontinuing the cycle of chronic
injury progression into tendinopathy. The therapeutic
outcome is potentially augmented by the analgesic effect,
which may accelerate mobilisation, promoting the main-
tenance of ROM and muscle strength.Inclusion criteria
Human studies included were randomised control trials
(RCTs) comparing efficacy of GTN patches with either pla-
cebo or a currently recognised treatment control. No re-
striction on dosage, time frame, or concurrent treatments
was made. RCTs addressing shoulder pathology related toFigure 2 Search strategy flow chart illustrating sequence of even
PICO evaluating tools. CRAAPZ currency, relevance, authority, acc
and outcome.SIS, verified via clinical examination or imaging, were
included in this review. Animal studies demonstrating the
involvement of NO in any form of tendon healing were also
included.Search strategy
Medline and Embase (via Ovid Platform), and the Cochrane
library were searched using key search terms to identify
relevant trials. Relevant articles’ references and citations
were also searched (Fig. 2). The combination of search
terms utilised was “Glyceryl Trinitrate” AND “Rotator Cuff”
OR “Shoulder Impingement”, which presented the results
discussed in the following section.
The 68 database results and 83 references or citations
were scanned manually for titles relating to “GTN in tendon
healing”, and the abstracts of those articles were screened
utilising the currency, relevance, authority, accuracy, and
purpose (CRAAP) assessment tool to determine if they met
the inclusion criteria. Studies not detailing pathology,
treatment routine, or outcomes were ineligible and
excluded. Four RCTs extracted from the databases and
references met the inclusion and eligibility criteria, and
were included in this review.Animal studies
The effects of NO and NOS on tendon healing have been
investigated in animal studies, principally via rat Achilles
tendon injury rather than shoulder pathologies, the mech-
anisms of which may be extrapolated to the rotator cuff
tendons.
The bulk of experiments performed can be categorised
as those demonstrating the correlation between injury and
the influx of NO or NOS, and monitoring the effect of NOS
inhibition or exogenous administration on tendon healing.
This has been followed by a spurt in clinical trials. In the
following subsections, we explore the animal data first.ts, database results, and exclusion process; utilising CRAAP and
uracy, and purpose; PICOZ population, intervention, control,
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Murrell et al [8] conducted a foundational investigation in
rats’ Achilles tendons, demonstrating the absence of NOS
activity in uninjured tendons, and a five-fold increase in
NOS activity after surgical division within the healing
tendon. Subsequent inhibition of NOS decreased failure
loads and cross-sectional area of the healing tendon
(p < 0.01 on Day 7). The proposition of NOS expression in
tendon injury or tendinopathy was supported by the con-
clusions made using the “overuse” modeldwhen rats
stimulated to run 1 hour/day on a treadmill were compared
with controls, an overexpression of NO precursors was
observed in the supraspinatus tendon post 14 days in the
experimental group [6].Inhibition of NOS
Xia et al [10] performed a follow-up study on 29 mice,
evaluating the effect of deleting the NOS gene on Achilles
tendon healing. Twenty-one NOS gene-deficient mice were
divided into two groups, the first of which was treated with
an NOS inhibitor (intraperitoneal) and the second remained
without treatment. The remaining eight “wild” mice with
intact NOS gene constituted the third control group. Tran-
section of the right Achilles tendon was performed in all
mice, and the tendons were subsequently harvested 7 days
postsurgery. Outcome measures were the cross-sectional
area, biomechanical force, and displacement of the
tendon. The NOS gene-deficient mice that were further
treated with an NOS inhibitor (Group 1) showed a significant
reduction in the cross-sectional area of healing, whereas no
significant difference was observed between the other two
groups (p < 0.01). No difference in failure or stress load was
elicited between the three groups. Thus, the study
concluded that the NOS gene deletion alone did not play a
significant role in healing; however, systemic NOS inhibition
reduced healing, inferring the importance of local NOS in
tendon healing and the presence of alternate pathways for
its production [10].Administration of NO
Yuan et al [11] histologically assessed the effect of exoge-
nous NO administration via the vehicle compound flurbi-
profen (NO-flurbiprofen), in comparison to flurbiprofen
alone, on healing of surgically divided rat Achilles tendons.
They found improved extracellular collagen matrix organi-
sation postsurgery in the NO-flurbiprofen and flurbiprofen
groups and improved tendon stress performance only in the
NO-flurbiprofen group, but no statistically significant
change in collagen mass in any of the experimental groups.
The aforementioned findings were supported by a trial
comparing subcutaneous injection of NO-paracetamol,
paracetamol, and the vehicle compound, reporting that
injection of paracetamol and the vehicle alone had a
similar effect, and no significant change in failure load was
elicited by any of the experimental groups. The NO-
paracetamol subcutaneous injection was shown to
improve tendon properties, including collagen organisationand content, in comparison to the other test groups,
reportedly consistent with the findings of human trials in
which NO improved tendinopathy-related signs and symp-
toms [13].
Thus, oral vehicle transmission of NO may not provide
the ideal platform for drug delivery. Transdermal patches
may offer an easy-to-use and proven alternative.
GTN human trials
There has been a paucity of clinical data on GTN patches in
tendon healing. However, this field has been exploded over
the last decade, with many institutions currently con-
ducting research on the same, including our own. There is
an absence of published RCTs in the literature exploring the
effect of GTN on SIS explicitly; thus, this review will eval-
uate the available RCTs that measure the efficacy of
transdermal GTN in a range of rotator cuff tendinopathies
involved in shoulder impingement (Table 1).
Shoulder tendinopathy
Giner-Pascual et al [14] conducted a double-blinded clinical
trial evaluating the efficacy of transdermal GTN patches in
treating shoulder pain and functionality, in 45 wheel-chair-
bound spinal cord injury patients presenting with concur-
rent shoulder tendinopathy. Diagnosis of rotator cuff
tendinitis or partial tears was made based on magnetic
resonance imaging findings (or ultrasonography when mag-
netic resonance imaging was contraindicated), in concor-
dance with the complaint of chronic shoulder pain (> 3
months) prior to inclusion in the study.
The participants were randomly assigned to an experi-
mental group (nZ 33) and a placebo group (n Z 12), each
respectively administered a quarter (1.25 mg) GTN patch or
placebo patch daily, on the lateral aspect of the shoulder.
This treatment pattern was maintained for over 6 months in
absence of additional pharmacotherapy or physical therapy
[14].
Outcome measures included awareness of pain (assessed
via a 0e10 VAS), functional movement [assessed via Spinal
Cord Injury Measurement (SCIM)], functional movement-
induced pain [assessed via Wheelchair Users Shoulder Pain
Index (WUSPI)], and manual assessment of ROM via goni-
ometry. Assessment of outcomes was performed before and
after treatment [14].
Comparison of the mean outcome scores revealed sig-
nificant improvement in the GTN experimental cohorts’
ROM (abduction, antepulsion, retropulsion, and internal
and external rotation) post-treatment (p < 0.005), whereas
a reduction in ROM was elicited in the placebo cohort
(p < 0.005). The mean pain scores (VAS and WUSPI) were
improved in the experimental group (p < 0.001) throughout
treatment; however, the placebo cohort demonstrated no
significant change in VAS scores and an increase in WUSPI
(increased pain induced by functional movement). There
was no significant difference in functional movement via
SCIM post-treatment in either group [14].
Nine of the initial 33 patients in the experimental group
did not complete the 6-month treatment routine, five due
to improvement of symptoms and four due to inability to
Table 1 Summary of the controlled trials conducted with GTN patches and a controlda comparison of the efficacy of the EG (in all cases GTN patch cohort) and the CG (other
treatment).
Trial Shoulder tendinopathy [14] Supraspinatus tendinopathy [4] Rotator cuff tendinitis [15] Supraspinatus
tendinitis [16]
Patient no. 45 53 48 20
Control Placebo Rehabilitation exercise Corticosteroid injection Placebo
Dosage 1.25 mg/24 h 1.25 mg/24 h 5 mg/24 h (3d) 5 mg/24 h
Time 6 mo 6 mo 3-, 15-d intervals 3 d
Pain score (VAS)a EG 5.42b 2.25 5b 1.75 21% 5 þ point reduction 7.05b 2
Pain score (VAS)a CG 5.33b 4.6 5.5b 4.25 79% 5 þ point reduction 6b 5.9
p <0.001 <0.05 <0.05 <0.0001
ROM (EG) Improved in every direction
(p < 0.05)
Increased in abduction and
internal rotation (p Z 0.02, 0.04)
Not reported Significant
improvement in joint
mobility (p < 0.0001)
Special test (EG) SCIM (p > 0.05) Increase in supraspinatus force
(p Z 0.05)
Not reported Pain duration
decreased (p < 0.0001)
% Adverse effects (EG/CG) 33% (7H þ 2 other) 16.6% (2H) 65% (15H þ 3 R) 33% (9H þ 1 R) 62% (15H) 16% (4 mild pain) 20% (2H) Nil reported
Authors’ conclusion regarding GTN patches Safe alternative for controlling
pain in shoulder pathology
Significantly improves pain
symptoms, ROM, and force, in
comparison to tendon
rehabilitation








CG Z control group; EG Z experimental group; GTN Z glyceryl trinitrate; H Z headache; R Z rash; ROM Z range of motion; SCIMZ Spinal Cord Injury Measurement; VAS Z visual
analogue scale.
a Adjusted among all studies (0e10).












GTN patches for shoulder impingement 17tolerate the treatment. Ten patients (33%) in this group
reported adverse events, seven of whom experienced
headaches and the other three reported single cases of
facial reddening, dizziness, and tachycardia. Six of the
initial 12 patients in the placebo group discontinued
treatment, five due to no improvement in symptoms and
one due to an inability to tolerate the treatment. Two pa-
tients (16.6%) in this group experienced headaches, which
was the only adverse event reported [14].
Supraspinatus tendinopathy
Paoloni et al [4] conducted a double-blind controlled trial in
53 patients (57 shoulders) with chronic supraspinatus ten-
dinopathy, over a period of 6 months, assessing the efficacy
of sustained GTN (1.25 mg/24 hours) application in com-
parison to rehabilitation exercise. The outcome parame-
ters, including severity of shoulder pain (0e4), power, ROM,
strength and ADL-related symptoms, concurrent monitoring
of compliance, and headaches, were assessed based on
daily diary entries.
The intention-to-treat cohort in comparison to the
rehabilitation-only cohort reported an overall reduction in
pain (p < 0.05); at 12 weeks, there was a decrease in
shoulder pain at night and at rest (0.03 and 0.04, respec-
tively) and further reduction in both cases by 24 weeks
(pZ 0.01 and pZ 0.03, respectively). The GTN group also
demonstrated increases in supraspinatus and external
rotation force (p < 0.01 and p < 0.05, respectively). No
significant differences were noted in subacromial tender-
ness (pZ 0.53), external rotation impingement (pZ 0.24),
and flexion ROM (pZ 0.36) in either cohort. Patients in the
treatment cohort experienced a significant increase in
headache-affected days (p Z 0.001) and consequently in
the amount of paracetamol used (p Z 0.001) throughout
the course of treatment, with 8% of patients (2/26) in the
GTN cohort ceasing treatment due to severe headaches.
Effect size was reported to be 0.26 for all outcomes [4].
Rotator cuff tendinitis
Pons et al [15] performed a randomised controlled trial in
48 patients comparing the efficacy of transdermal GTN
(5 mg patch) and corticosteroid infiltration (1 mL triam-
cinolone acetonide with a local anaesthetic) in rotator cuff
tendinitis. The diagnostic inclusion criteria consisted of
pain, positive impingement sign, and a positive rotator cuff
tendon minor test; patients were also not responsive to oral
non-steroidal anti-inflammatory drugs (NSAIDs). Patients
were randomly distributed into two groups of 24: “Group A”
patients received a posterior-approach corticosteroid in-
jection and “Group B” patients were administered GTN
patches over the shoulder region with the most severe pain
for 3 days. Complete improvement corresponded with
cessation of treatment; otherwise, procedures were
repeated up to three times at 15-day intervals [15].
The primary outcome measured pain (via a VAS, 0e10),
treatment failure (defined as a reduction in pain score
by < 3 points), partial improvement (a reduction by 3e5
points), and complete improvement (>5-point reduction).
An outcome assessment was performed at baseline and 7days post each treatment routine to measure the adverse
effects as a secondary outcome [15].
In Group A, consisting of intention-to-treat patients
receiving corticosteroids, 19 patients (79%) demonstrated
complete improvement, three patients (12.5%) demon-
strated partial improvement, and two patients (8.3%)
demonstrated treatment failure. The adverse event eli-
cited was pain (mild) at the site of injection in four patients
(16.6%). In the GTN patch cohort, Group B, five patients
(20.8%) demonstrated complete improvement, five patients
(20.8%) showed partial improvement, and 14 patients
(58.3%) had failure of treatment. Fifteen patients (62.5%) in
the GTN cohort experienced headaches, causing eight pa-
tients (33.3%) to abandon treatment. The difference be-
tween Groups A and B was reported to be statistically
significant. Pons et al [15] concluded that GTN patches
were not as efficacious as corticosteroid infiltration and led
to a significant increase in adverse events, resulting in
abandonment of treatment; thus, treatment failure were
not a suitable alternative.
Supraspinatus tendinitis
Berrazueta et al’s [16] double-blinded placebo-controlled
trial assessed GTN’s analgesic capacity, in supraspinatus
tendinitis-induced “shoulder pain syndrome”. Twenty pa-
tients (10 M/10 F) were randomised, and equal numbers of
patients received either a 5 mg GTN patch or a placebo
equivalent, applied proximal to the region with the most
severe pain, over 3 consecutive days. Pain evaluation was
carried out before treatment and 24e48 hours subse-
quently via an analogue scale (0e10). Patients were also
monitored for duration of the pain (hours) and joint motion
restriction (% restriction) [16].
Post-treatment follow-up demonstrated a significant
reduction in pain intensity in the GTN cohort at the 24-hour
mark (from 7 to 4.5; p < 0.001), with further reduction at
48 hours (to 2; p < 0.0001); however, no change in pain was
elicited in the placebo group. The mean duration of pain
also reduced with GTN (from 1.7 to 0.1; p < 0.0001), with
no significant variation in the placebo group. Joint mobility
improved significantly with GTN (from 2.0 to 0.1;
p < 0.0001), but did not change in the placebo group.
Adverse effects were limited to two patients experiencing
headaches with GTN administration. Further assessment
after 15 days demonstrated the entire GTN cohort and five
placebo patients (on analgesic medication) to be symptom
free, while the remaining placebo patients remained with a
slight pain (intensity 3.6) [16].
Discussion
This review has explored the evidence surrounding NO’s
effect on tendon healing, its application in a variety of
animal studies, and the efficacy of its administration via
GTN patches in clinical trials. The literature suggests that
NO is an important biochemical factor in collagen deposi-
tion and organisation. Animal studies demonstrate that its
inhibition impedes healing and addition augments it. This
has sparked a variety of clinical trials, which have reported
significant pain reduction with GTN.
18 Y. Assem, M. AroraA common primary outcome of the four trials related to
SIS pathology explored in this review was the analgesic
capacity of the treatment, measured from the differences
in VAS pain scores before and after intervention. The re-
sults have been converted to the mean pain reduction from
baseline, as demonstrated by graph of Fig. 3. Three of the
four trials show a significant (p < 0.05) reduction in the
mean pain in the GTN cohort in comparison to the placebo
cohort, while the trial conducted by Pons et al [15] showed
a significant reduction in pain for the control cohort
(corticosteroid injection) in comparison to the GTN cohort.
Additional outcomes, including ROM, functionality, and
force, were not standardised across the trials; however, the
three placebo control trials demonstrated a significant
improvement in these functions in the GTN cohort. Overall,
a significant increase in GTN-related side effects, namely,
headaches, was observed, impeding treatment in a number
of patients in each trial.
Heterogeneity of trial design
There is heterogeneity in the available clinical trials, in
terms of GTN administration, dosage and time, diagnostic
criteria for inclusion, comparative controls, and final
outcome measures. This confounds attempts to formulate a
priori conclusions of efficacy from the results.
Administration
The application of a 5 mg GTN patch over 3 consecutive
days in earlier studies deviates from the daily application of
a 1.25 mg patch utilized in recent studies. This creates
variability in the pharmacokinetics, whereby the absorption
in the vasculature is changed. The consequent inconsis-
tency in plasma concentration, compounded by the pre-Figure 3 Graphs comparing the mean pain reduction be-
tween the GTN patch experimental cohort and the control
cohort, categorised by trial dates. Pain reduction was calcu-
lated from VAS end outcomes. * Statistically significant
(p < 0.05) pain reduction in GTN cohort. GTN Z glyceryl tri-
nitrate; VASZ visual analogue scale.existing interindividual variation, leads to an unpredictable
treatment effect.
Outcome time points
The diversity of the outcome assessment time points
potentially confounds the reported results. The 6-month
postintervention assessment in Giner-Pascual et al [14] and
Paoloni et al [4] demonstrate a positive effect in the GTN
cohort’s pain scores and ROM. Berrazueta et al [16]
assessed the pain and restriction of joint motion 3 days
postintervention, perceivably a measure of acute analgesic
capacity rather than an adequate quantification of GTN’s
healing aptitude.
Pons et al [15] assessed outcomes at 7-day intervals post
3-day GTN application or corticosteroid injections. Discon-
tinuity of GTN application in between follow-ups and short-
term assessment do not effectively gauge the healing
potential of GTN, in comparison to the control in which this
is sufficient time to alleviate symptoms. Therefore, the
healing capacity of GTN may have been underestimated in
the two initial studies [15,16].
Control
The use of a consistent control in studies allows the vali-
dation of results that can be replicated. The available
studies that we have reviewed lack consistency, comparing
GTN to placebo, rehabilitation, or corticosteroid controls,
making it difficult to evaluate the validity of each individ-
ualised study, as the results are not standardised.
Randomisation
Giner-Pascual et al [14] and Paoloni et al [4] utilised patient
arrival time points and coding randomisation, respectively,
to eliminate bias. Pons et al [15] significantly reduced the
risk of randomisation bias by assigning patients through a
random number table. There was no description of ran-
domisation in the study of Berrazueta et al [16]; thus, there
remains an unpredictable risk of randomisation bias.
Blinding
Trials of Giner-Pascual et al [14], Paoloni et al [4], and
Berrazueta et al [16] had adequate double blinding of pa-
tients and clinical examiners, utilising identical placebo
patches in the control group. Pons et al’s [15] paper did not
describe any blinding of either patients or examiners, the
variable invasiveness of the intervention rendering the
process difficult, albeit a replica patch or injection may
have sufficed.
Methodology
Heterogeneity of end outcomes makes it difficult to validate
individualised results and compare the overall efficacy of
the treatment cohorts. Pons et al [15] assessed only the VAS
pain score and the adverse event rate; we do not believe
that subjective pain assessment alone is sufficient to
GTN patches for shoulder impingement 19indicate the efficacy of GTN, particularly when significant
symptoms of shoulder impingement have been ignored,
compared to the other studies all of which measured pain,
adverse events, and ROM. The subjectivity in outcome se-
lection potentiates reporting bias, whereby significant out-
comes may be selectively expressed in the method.
Supplementary measures included shoulder functional
movements (via SCIM) and muscle force [14]. Pain scale
intertrial variation also exists, albeit it is the only outcome
comparable across all trials.
The absence of the aforementioned clinically significant
secondary outcomes will negatively impact the clinician’s
decision-making process in trialling this treatment.
Standardised long-term follow-up assessment is absent
in all four studies; this would be a valuable addition to the
literature, permitting a paralleled comparison with current
interventions. It would also reduce the risk of reporting
bias, where positive effects may have been temporary.
Long-term assessment would also facilitate the application
of GTN as a definitive intervention and not just an adjuvant.Outcome reporting
The outcomes reported by Giner-Pascual et al [14] and
Paoloni et al [4] parallel those detailed in methodology;
though there is a selective reporting of numerical p values
at time points of significance, the reader may assume that
non-numerical outcomes are insignificant. Pons et al [15]
deviates from the methodological plan utilizing a defined
categorical scale, consisting of the three-components;
complete improvement, partial improvement and treat-
ment failure. This is ineffective in comparison to the initial
baseline to post-treatment continuous scoring system.Statistical analysis
Giner-Pascual et al’s [14] trial was the only trial to detail
the multivariate analysis of variance of the “intention-to-
treat” group in their methodology, adequately evaluating
the association between the independent variable (i.e.,
GTN) and the dependent variables [VAS pain, ROM, and
function (SCIM)]. Paoloni et al [4] and Berrazueta et al [16]
utilised the ManneWhitney U test, a nonparametric test
showing greater efficiency than a simple t test in the non-
normal distributions. The non-normal distribution is pre-
dictable in the context of pre-existing interindividual vari-
ation of NO plasma concentration and responses to
treatment. Pons et al’s [15] trial did not provide sufficient
information regarding their statistical analysis, a prospect
for analytical bias.Future implications in clinical practice and
research
The results explored throughout this review are promising;
there is evidence that GTN shows analgesic effects in SIS, as
well as increasing ROM and function, facilitating a platform
for further research to validate findings and increase their
statistical power for application in the clinical setting.Based on a systematic review of the available treatment
modalities, we concluded that the first-line therapy should
consist of NSAIDs, which provide temporary short-term re-
lief and physical therapy (stretching and strengthening
exercises), whereas therapeutic adjuvants such as
phonopheresis, ionophoresis, and ultrasound lack appro-
priate evidence [19]. A meta-analysis by Arroll [20]
revealed subacromial corticosteroid injections to be more
effective than NSAIDs. Corticosteroids were found to pro-
vide short-term relief; however, there was not sufficient
evidence to demonstrate longer-term benefits. Andres and
Murrell [19] suggested transdermal GTN as a viable alter-
native if other treatments failed and surgical debridement
as a final option subsequent to exhausting all other in-
terventions, as it is associated with significant morbidity
and cost, with only “modest” success.
In future research, high-quality trials should maintain a
consistentGTNdosage regimenand interventional timespan.
Comprehensive secondary outcome measures and long-term
follow-up are highly recommended, enabling valuable com-
parison with currently recognised interventions. Nonbiased
randomisation anddouble blinding are essential, the physical
appearance of the placebo replicating that of the treatment.
GTN is a simple-to-apply, noninvasive, low-morbidity inter-
vention, with great potential to become a mainstay treat-
ment, if larger, multicentre trials with greater strength
reproduce the aforementioned results.
Conclusion
The clinical effect of GTN patches in SIS needs to be sub-
stantiated through supplementary high-quality trials, with
larger cohorts and consistent pathology. The primary con-
tingency is counteracting the common adverse consequence
of headaches. Little evidence exists for its equitable ther-
apeutic capacity to current treatment, such as corticoste-
roid use or muscle strengthening; thus, future comparative
trials will reveal the overall efficacy of this treatment.
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